For a patient with oligometastatic breast cancer that has completed adequate local therapy, would you consider ablating synchronous oligometastatic disease?

The prospective studies which are conducted for locoregional treatment for synchronous metastases didn't include treating metastatic disease with SABR. In practice, if we go the route of LRT in select subset, then consider SABR also, if still visible after systemic treatment.